Autonomic Dysreflexia: Atypical Complication from Immediate Release Tapentadol
DOI:
https://doi.org/10.17140/TFMOJ-6-136Keywords:
Spinal cord injury, Transverse myelitis, Pharmacokinetics, OpioidsAbstract
Neurological disorders are a ubiquitous part of our lives, and with innovative technological advancements there are increasing numbers of people being diagnosed with a variety of conditions. While these advances uncover the underlying pathological process, the requisite need to manage a patient’s condition necessitates renewed vigour in the realm of key therapeutics. This case study looks at a patient with a rare neurological condition, transverse myelitis (TM), and a complication that many spinal cord injury patients suffer, autonomic dysreflexia (AD). However, what makes this case unique is when the patient was administered with immediate-release Tapentadol, a synthetic opioid, the patient suffered more frequent and prolonged attacks of AD. The exploration of the functional anatomy of TM as it applies to this case is highlighted, and how the role of Tapentadol was a causative agent in increasing the patient’s AD.
References
Valencia-Sanchez C. Transverse Myelitis. Web site. https://best-practice.bmj.com/topics/en-us/1061. Accessed February 1, 2021.
Turkington C. Transverse Myelitis. In: Hiam D, ed. The Gale En-cyclopedia of Neurological Disorders. 3rd ed. Farmington Hills, Michi-gan: Gale; 2017.
Krishnan C, Greenberg B. Transverse Myelitis. Web site. https:// www.uptodate.com/contents/transverse-myelitis. Accessed 15 December, 2020.
Abrams G and Wakasa M. Chronic complications of spinal cord injury and disease. In: Aminoff M, Silverira M, Wilterdink J, ed. Autonomic Dysreflexia. Alphen aan den Rijn, Netherlands: Wolters Kluwer; 2019.
Linsenmeyer T. Acute management of autonomic dysre-flexiaL adults with spinal cord injury presenting to health-care facilities. J Spinal Cord Med. 1997; 20(3): 284-309. doi: 10.1080/10790268.1997.11719480
Purves D, Augustine G, Fitzpatrick D, Hall WC, Lamantina AS, Mooney RD, et al. Neuroscience: International Edition. 6th ed. New York, USA: Oxford University Press; 2019.
Standring S. Gray’s Anatomy: The Anatomical Basis for Clinical Prac-Submit your article to this journal | https://openventio.org/submit-manuscript/ 12 Diaz C et al tice. 42nd ed. New York, USA: Elsevier; 2020.
Pasternak G. Opioid receptors. In: Schmidt R, Willis W, eds. Encyclopedia of Pain. Heidelberg, Germany: Springer; 2007.
Kerrigan S, Goldberger B. Opioids. In: Kerrigan S, Levine B, eds. Principles of Forensic Toxicology. 5th ed. Cham, Switzerland: Springer; 2020: 347-369.
Stollenwerk A, Sohns M, Heisig F, Elling C, von Zabern D. Review of post-marketing safety data on Tapentadol, a centrally acting analgesic. Adv Ther. 2018; 35: 12-30. doi: 10.1007/s12325- 017-0654-0
Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degen-hardt L. Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing study protocol. BMJ Open. 2018; 8(3): e020006. doi: 10.1136/bmjopen-2017-020006
Langford RM, Knaggs R, Farquhar-Smith P, Dicken-son AH. Is Tapentadol different from classical opioids? A re-view of the evidence. Br J Pain. 2016; 10(4): 217-221. doi: 10.1177/2049463716657363
Sansom L. Oral extended-release products. Australian Presciber. 1999; 22: 88-90. doi: 10.18773/austprescr.1999.0
Albertson TE. Opiates and opioids. In: Olson K, Anderson BI, Benowitz NL, Blanc PD, Clark RF, Kearney TE, et al. Poisoning and Drug Overdose. 7th ed. NY, USA: McGraw Hill; 2019. Case Report | Volume 6 | Number 1|
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Toxicology and Forensic Medicine (TFM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
